Genetic testing to assess pathogenic variants in genes commonly implicated in FH, namely the LDLR, PCSK9, and apolipoprotein B100 (APOB), could not be performed in our patient due to limited local availability of testing facilities and financial constraints. Despite this limitation, cascade screening of first-degree relatives should be prioritized in future care, as early identification and treatment of affected individuals can significantly reduce cardiovascular morbidity and mortality associated with FH. The gene discussed is APOB; the disease is familial hyperaldosteronism.